News|Articles|November 19, 2026

How BRCA Testing Shapes Maintenance Therapy in Pancreatic Cancer

Listen
0:00 / 0:00

Key Takeaways

  • Germline testing should be ordered promptly at diagnosis for all pancreatic cancer patients to ensure BRCA status is available when maintenance discussions arise after platinum induction.
  • Maintenance olaparib eligibility requires metastatic disease, deleterious/suspected deleterious germline BRCA1/2, and nonprogression after ≥16 weeks of first-line platinum; stable disease can qualify with companion diagnostic confirmation.
SHOW MORE

Early germline BRCA testing identifies patients with metastatic pancreatic adenocarcinoma who can be considered for olaparib maintenance if their disease has not progressed after at least 16 weeks of first-line platinum chemotherapy.

Stable disease after 16 weeks of first-line platinum-based chemotherapy can open a conversation about switching to oral maintenance. For an adult with metastatic pancreatic adenocarcinoma, whether olaparib (Lynparza; AstraZeneca, Merck) is an FDA-approved option depends on a result the oncology team can obtain much earlier: a qualifying germline BRCA1 or BRCA2 variant. World Pancreatic Cancer Day, observed on November 19, offers a reminder to make germline testing part of the initial workup so the result is available when the patient and care team are weighing whether to switch.1-3

Order Germline Testing Before the Maintenance Decision

The Pancreatic Cancer Action Network recommends germline testing for all patients with pancreatic cancer as soon as possible after diagnosis. Germline testing looks for inherited variants, which can have implications for the patient’s relatives. Tumor profiling looks for alterations in the cancer itself. A tumor report that flags a BRCA alteration should prompt the team to check whether germline testing has been completed, because the pancreatic indication for olaparib requires a qualifying germline result.2,3

During the initial treatment review, oncology pharmacists can check whether germline testing has been ordered and where the final report will appear in the medical record. A chart entry that says “BRCA positive” leaves the origin and classification of the variant unclear. Reviewing the original report gives the team time to resolve an ambiguous result and arrange genetics follow-up when a finding has implications for relatives.2,3

Confirm Eligibility Before Switching to Maintenance

The FDA indication covers adults with metastatic pancreatic adenocarcinoma and a deleterious or suspected deleterious germline BRCA variant whose disease has not progressed during at least 16 weeks of first-line platinum-based chemotherapy. The prescribing information calls for an FDA-approved companion diagnostic. Stable disease can meet the nonprogression criterion. At prescription review, pharmacists can verify how long the patient received platinum, check the latest disease assessment, and make the germline report available for a prior authorization request.2,4

What the POLO Trial Showed

In the phase 3 clinical trial, POLO (NCT02184195), 154 patients were randomly assigned to receive maintenance olaparib or placebo after first-line platinum-based chemotherapy. Median progression-free survival was about 7.4 months with olaparib and 3.8 months with placebo (HR, 0.53; 95% CI, 0.35-0.82; P = .004). In the final analysis, median overall survival (OS) was 19.0 months with olaparib and 19.2 months with placebo (HR, 0.83; 95% CI, 0.56-1.22; P = .35). The OS difference was statistically nonsignificant.4,5

For patients considering the switch, the trial supports a longer period before progression or death with olaparib compared with placebo. The comparison with placebo leaves open whether switching to olaparib offers an advantage over continuing chemotherapy. That distinction matters when a patient asks what they can expect to gain from stopping infusions and starting an oral regimen taken twice daily.4,5

Plan for the First Fill and Follow-up

The usual olaparib dose is 300 mg orally twice daily, with a reduction to 200 mg twice daily for patients with a creatinine clearance of 31 to 50 mL/min. Pharmacists can review prescription and nonprescription medications for strong or moderate CYP3A inhibitors and inducers, which the label advises avoiding. Before treatment begins, hematologic toxicity from prior chemotherapy should have recovered to grade 1 or less. The label calls for a complete blood count at baseline and monthly thereafter. It also calls for checking bilirubin and transaminases at baseline and throughout treatment.2

Fatigue and nausea were common with olaparib in the POLO trial, and anemia can also contribute to worsening fatigue. At the first fill, pharmacists can confirm the date of the next blood draw and give the patient a clear point of contact if symptoms worsen or nausea interferes with dosing. Patients who miss a dose should take the next dose at the usual time. The first refill is another opportunity to check whether symptoms have disrupted dosing and whether the patient has completed the planned blood work.2,4

REFERENCES
  1. World Pancreatic Cancer Day 2026. World Pancreatic Cancer Coalition. Accessed November 19, 2026. https://www.worldpancreaticcancercoalition.org/world-pancreatic-cancer-day-2026/
  2. Lynparza. Prescribing information. AstraZeneca Pharmaceuticals LP; 2025. Accessed November 19, 2026. https://www.accessdata.fda.gov/drugsatfda_docs/label/2025/208558s031lbl.pdf
  3. Genetics and hereditary factors of pancreatic cancer. Pancreatic Cancer Action Network. Accessed November 19, 2026. https://pancan.org/facing-pancreatic-cancer/about-pancreatic-cancer/risk-factors/genetic-hereditary/
  4. Golan T, Hammel P, Reni M, et al. Maintenance Olaparib for Germline BRCA-Mutated Metastatic Pancreatic Cancer. N Engl J Med. 2019;381(4):317-327. doi:10.1056/NEJMoa1903387
  5. Kindler HL, Hammel P, Reni M, et al. Overall Survival Results From the POLO Trial: A Phase III Study of Active Maintenance Olaparib Versus Placebo for Germline BRCA-Mutated Metastatic Pancreatic Cancer. J Clin Oncol. 2022;40(34):3929-3939. doi:10.1200/JCO.21.01604

Related to this article